Update On Long-Term Curcumin Patients
The case studies section of my website gives an overview of the health status of some of my long-term curcumin patients. In this post I provide an update on the health status, and implications, for two of these patients.
As per Ian M's case report, he has been taking 2.3 grams C3 complex curcumin daily since 2007. To recap, when Ian first entered our pilot study, his paraprotein level was 26 grams per litre. His paraprotein level as of January 2020 was 8.6 grams per litre – a 67% reduction in paraprotein over a 13 year period. His latest blood test in 2022 showed a paraprotein level of 6.7 ie there has been a further reduction (74% since baseline) in his paraprotein level since 2020.
Ian’s free light chain ratio was 23.5 at the start of the study. His free light chain ratio as of January 2020 was 5.7 - a 76% reduction and in 2022, Ian’s rFLC was again 5.7 ie the 76% reduction has been maintained. His kappa light chain (the involved light chain) has shown a 72% reduction and the involved immunoglulin ie IgG has shown a 57% reduction over the 15 plus years of curcumin therapy. Of interest, and this data has not yet been published, other markers of his disease have also improved ie his haemoglobin (Hb) and other immunoglobulins ie IgM and IgA have increased over the years.
An update on Kenneth B
Regarding Kenneth B, also described under ‘case reports’, who was diagnosed with smoldering myeloma (SMM) in 2006 at the age of 63. He entered our study in 2010. When Ken first entered the study, his paraprotein level was 31.7 grams per litre and as of January 2020 was 17.7 grams per litre – a 44% reduction in paraprotein over a 10 year period. As of 2022, his paraprotein remained stable at 17.8 ie maintaining a 44% reduction in paraprotein load on curcumin therapy alone.
Ken’s free light chain ratio was 0.3 in 2010 and in 2022 it measured 0.5 ie showing an improvement. Ken’s involved immunoglobulin (IgG) showed a 49% reduction and his involved light chains (lambda) showed a 10% reduction over the 12 year period of curcumin therapy. Ken continues to take 6 grams curcumin daily as C3 complex in a divided dose.
What this means for both Ian and Ken
Without early curcumin intervention, Ian’s disease would have, at best, remained stable – at worst it would have progressed into Smoldering Myeloma and possibly even Multiple Myeloma.
For patients like Ken (with SMM), there is a 50% chance that the disease would have progressed to Multiple Myeloma - a very aggressive type of cancer - within 5 years. However, with curcumin intervention not only has Kenneth not progressed after 12 years, but his disease markers have actually improved.